Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cemiplimab companion diagnostic - Agilent

Drug Profile

Cemiplimab companion diagnostic - Agilent

Alternative Names: PD-L1 IHC 22C3 pharmDx for Autostainer Link 48 for cemiplimab; PD-L1 IHC 22C3 pharmDx for cemiplimab; PD-L1 IHC 22C3 pharmDx kit for LIBTAYO®; PD-L1 immunohistochemistry 22C3 assay for cemiplimab

Latest Information Update: 24 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dako A/S
  • Developer Agilent Technologies; Regeneron Pharmaceuticals; Sanofi
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Non-small cell lung cancer
  • Phase II Squamous cell cancer

Most Recent Events

  • 20 Jul 2021 Registered for Non-small cell lung cancer (Diagnosis) in European Union, Iceland, Liechtenstein, Norway (unspecified route)
  • 19 Jul 2021 Preregistration for Non-small cell lung cancer (Diagnosis) in European Union (unspecified route) before July 2021
  • 22 Feb 2021 Registered for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top